Mount Sinai Technologies

Discover the various technologies developed by Mount Sinai inventors that are currently helping the patient population.


Nasal spray for treatment-resistant depression

For patients of treatment-resistant depression and adults with major depressive disorder with acute suicidal ideation or behavior, Janssen’s SPRAVATO® (esketmine) CIII nasal spray received FDA approval in 2019, in conjunction with an oral antidepressant.

Learn more
Pain treatment for endometriosis

Orilissa® is the first FDA-approved oral regimen that specifically helps to ease the moderate to severe pain that accompanies endometriosis.

Learn more
Therapy for acute hepatic porphyrias

The translational research by Robert J. Desnick, MD, contributed to the development of GIVLAARI®, an RNA interference therapy for acute hepatic porphyrias, with Alnylam Pharmaceuticals.

Learn more
Nasal spray influenza treatment

Mount Sinai researchers developed technology that serves as the foundation for a nasal spray to protect against Influenza A and B sub-types.

Learn more
Enzyme replacement therapy for Fabry disease

Fabrazyme, based on technology developed by Mount Sinai researchers, is the first-ever U.S. approved treatment for Fabry disease, an inherited condition caused by genetic variation. Licensed to Sanofi.

Learn more


COVID-19 antibody test technology

Semi-quantitative SARS-CoV-2 serology test to detect the presence or absence of COVID-19 antibodies.

Learn more
Self-testing system to prevent blood clots

A self-monitoring test system that allows patients to measure the effects of anticoagulation therapy for blood clotting events.

Learn more
Platelet reactivity system to identify antiplatelet-related bleeding risk

VerifyNowTM is an FDA-approved test that measures and quantitates platelet responsiveness to a variety of antiplatelet medications to improve treatment decisions. VerifyNowTM is manufactured and distributed by Werfen.

Learn more
Diagnostic test for spinal muscular atrophy

Carrier screening tool for the detection of spinal muscular atrophy (SMA) in silent carriers, developed and launched by researchers from the Department of Genetics and Genomic Sciences at the Icahn school of Medicine at Mount Sinai.

Learn more


Patient-specific 3D printed joint implants

Technology consists of a semi-autonomous surgical robot and customized joint implants, and is the basis for Monogram Orthopedics, a startup launched by Mount Sinai researchers.

Learn more
Annuloplasty rings to improve tricuspid valve functioning

Annuloplasty ring to provide high-quality valve repair in patients suffering from tricuspid valve disease. Licensed to Medtronic.

Learn more
Annuloplasty rings to improve mitral valve functioning

Annuloplasty ring to provide higher quality valve repair in patients suffering from mitral valve disease. Licensed to Edwards Lifesciences.

Learn more
Excimer laser technology to treat pigment-loss skin condition

Highly targeted beam of UVB light to treat vitiligo, which is a long-term skin condition characterized by skin patches that have had pigment loss. Licensed to Strata Skin Sciences.

Learn more


Platform for improved outcomes of progressive kidney disease

KidneyIntelX™ delivers critical insights to assess the risk of progressive kidney function decline in patients with type 2 diabetes and early-stage chronic kidney disease to optimize outcomes and improve clinical management. Licensed to Renalytix.

Learn more
Resilience assessment and treatment methodology for IBD patients

GRITT™ combines a resilience assessment with personalized psychosocial care plans for disease management of Inflammatory Bowel Disease (IBD) patients, validated to significantly improve outcomes and reduce expensive unplanned care. Licensed to Trellus Health.

Learn more
Mobile app for IBD symptom tracking and care team communication

HealthPROMISE is a prescribed mobile application that assesses the impact of electronic patient reported outcomes on improving patients’ quality of life. Licensed to Rx.Health.

Learn more